Which medication used to treat Parkinson's disease is categorized as an MAO-B inhibitor?

Prepare for the Adult-Gerontology Acute Care Nurse Practitioner Test. Study with interactive quizzes and detailed explanations. Boost your exam readiness with our diverse question formats and in-depth content coverage.

Multiple Choice

Which medication used to treat Parkinson's disease is categorized as an MAO-B inhibitor?

Blockade of MAO-B raises brain dopamine by slowing its breakdown, helping to improve motor symptoms in Parkinson disease. Rasagiline is a selective, irreversible MAO-B inhibitor, so it mainly inhibits the MAO-B enzyme with minimal effect on MAO-A. This increases dopamine availability in the striatum, which can improve bradykinesia and rigidity. It can be used as monotherapy in early disease or as an add-on to levodopa to smooth motor fluctuations, and it’s typically given once daily. Among the options, rasagiline stands out as the classic MAO-B–inhibitor choice, with fewer stimulant metabolites than selegiline and a straightforward, pure MAO-B mechanism compared with safinamide’s additional actions.

Blockade of MAO-B raises brain dopamine by slowing its breakdown, helping to improve motor symptoms in Parkinson disease. Rasagiline is a selective, irreversible MAO-B inhibitor, so it mainly inhibits the MAO-B enzyme with minimal effect on MAO-A. This increases dopamine availability in the striatum, which can improve bradykinesia and rigidity. It can be used as monotherapy in early disease or as an add-on to levodopa to smooth motor fluctuations, and it’s typically given once daily. Among the options, rasagiline stands out as the classic MAO-B–inhibitor choice, with fewer stimulant metabolites than selegiline and a straightforward, pure MAO-B mechanism compared with safinamide’s additional actions.

More practice questions